Home / Multiple Sclerosis

Multiple Sclerosis

Recent Survey Reveals that Multiple Sclerosis Patients Want More Information on Brain Atrophy

SUMMIT, N.J.–(BUSINESS WIRE)–A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. Sixty-three percent of …

Read More »

Teva Presents 25-Year Safety Data from Longest Continuous Trial of Copaxone for Treatment of Relapsing Forms of Multiple Sclerosis

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced safety and tolerability results representing 25 years of data from the open-label extension study of the original U.S. pivotal trial of COPAXONE®(glatiramer acetate injection) for the treatment of relapsing forms of multiple sclerosis (RMS). The extension study initially examined …

Read More »

FDA Accepts Novartis’ NDA for Investigational Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis

Basel, October 08, 2018 – Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s New Drug Application (NDA) and Marketing Authorization Application (MAA) respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS) in …

Read More »

Accelerated Cure Project Collaborates with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis

WALTHAM, Mass., Oct. 2, 2018 /PRNewswire/ — Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) today announced it has entered into a ground-breaking collaboration with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, to capture and integrate the perspectives of people affected by …

Read More »

Novartis Announces Publication of Landmark Study Demonstrating Significant Benefit of Gilenya in Children and Adolescents with MS

Basel, September 12, 2018 – Novartis today announced that The New England Journal of Medicine (NEJM) has published full results from the landmark Phase III Gilenya® (fingolimod) PARADIGMS study, the first-ever controlled, randomized study specifically designed for children and adolescents (aged 10 to 17) with relapsing forms of MS (RMS). Children and adolescents with MS experience …

Read More »

MediciNova Announces the Publication of Results of the Phase 2b Trial of Ibudilast in Progressive MS

LA JOLLA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the New England Journal of Medicine has published results of the SPRINT-MS Phase 2b …

Read More »

Genentech Announces New Ocrevus Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology (EAN) from June 16-19 in Lisbon, Portugal. The new Phase III data analyses show OCREVUS may …

Read More »

FDA Approves Novartis’ Gilenya for Pediatric Patients with Relapsing Multiple Sclerosis

Basel, May 11, 2018 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), making it the first disease-modifying therapy indicated for these patients[2]. This …

Read More »

Prime Therapeutics Finds Poor Adherence to High-Cost Multiple Sclerosis Therapy

PAUL, Minn., April 23, 2018 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime), using real-world integrated medical and pharmacy data, show members with multiple sclerosis (MS) had 8.3 times higher annual total health care expense than members without MS. More than 80 percent of the …

Read More »

Ocrevus Significantly Reduces Disease Activity and Disability Progression in Relapsing Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple …

Read More »